DBV Technologies SA is a French biopharmaceutical firm headquartered in Bagneux, France.
DBV Technologies SA (Euronext: DBV) is a French biopharmaceutical firm headquartered in Bagneux, France.
DBV Technologies is most well-known for developing Viaskin technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. DBV Technologies novel approach to allergy treatment is focused on eliciting an immune response by targeting the antigen-presenting cells in the skin epidermis.
The antigens (allergens) are delivered to the skin using DBV Technologies unique worldwide patented delivery system, Viaskin. Viaskin Peanut is the first peanut desensitization product ever developed for peanut allergies, a huge unmet medical need; Viaskin Milk is specifically designed for patients with severe IgE-mediated milk allergies.
It is the first medical desensitization product designed for cows milk protein allergy. Viaskin in development: This technology is very versatile and could be adapted very easily to other allergens for specific geographical needs.
It also has an allergy testing system which works in a similar way. DBV Technologies' three target allergies represent a total market of over $5 billion.